New hope for frail leukemia patients: 3-Drug combo targets Treatment-Resistant cancer
NCT ID NCT05566054
Summary
This study is testing whether adding a drug called chidamide to an existing two-drug combination (venetoclax and azacytidine) works better for newly diagnosed acute monocytic leukemia patients who are too old or frail for intensive chemotherapy. The trial aims to see if this three-drug approach leads to more complete remissions and longer survival while monitoring side effects. Researchers hope the combination will overcome common resistance mechanisms seen in this aggressive blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.